A phase II randomized controlled trial evaluating the immunogenicity and safety of a recombinant aP vaccine and various Tdap vaccine formulations in healthy women of child bearing age
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs DTaP vaccine (Primary) ; Pertussis acellular vaccine (Primary) ; DTaP vaccine
- Indications Pertussis
- Focus Pharmacodynamics
- Sponsors BioNet-Asia
- 11 Sep 2018 Status changed from recruiting to completed.
- 20 Aug 2018 Status changed from not yet recruiting to recruiting.
- 19 Jun 2018 New trial record